Use of REDD1 Inhibitors to Dissociate Therapeutic and Adverse Atrophogenic Effects of Glucocorticoid Receptor Agonists

Description:

Thank you for your interest in this technology. Please see our technology brief here: https://app.in-part.com/articles/Zd8gEG1x73KW

Category(s):

Therapeutic

Download as PDF

For Information, Contact:

Felipe Araujo

Managing Director, Business Development and Licensing

Icahn School of Medicine at Mount Sinai

felipe.araujo@mssm.edu

Inventors:

Joel Dudley

Keywords:

Dermatology